Russia races to develop groundbreaking CAR-T therapy for rheumatic diseases by 2030

Russian scientists are working to develop the country's first full-cycle production of CAR-T cell therapies for severe rheumatic diseases by 2030. Currently, no such treatments exist in Russia, despite these conditions being among the most common connective tissue and joint disorders. Early trials abroad have shown promising results, with many patients achieving long-term remission after a single infusion.

CAR-T cell therapy works by extracting a patient's immune T-cells, genetically modifying them, and reintroducing them to target diseased cells. In global trials, such as Germany's CASTLE study, this approach has halted disease progression in severe cases of lupus and systemic sclerosis. Most participants no longer needed medication after treatment.

In Russia, a specialised laboratory at Novosibirsk State University is now developing key components, including viral vectors for gene delivery. A small production facility will also be built within a local clinic to support on-site manufacturing. The project aims to treat severe joint damage and other rheumatic diseases under hospital exemption rules.

While the therapy shows high efficacy, it remains experimental worldwide, with no approvals outside phase 1/2 trials. Production is complex, but the potential for long-term, drug-free remission makes it a significant advancement.

If successful, Russia's initiative could provide a domestic solution for patients with severe rheumatic conditions by 2030. The therapy's ability to restore immune tolerance and eliminate the need for ongoing medication marks a major shift in treatment approaches. For now, further trials and production scaling remain critical next steps.